Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancerEiichi Sato, Kunle Odunsi, Gerd Ritter et al.|Proceedings of the National Academy of Sciences|2005Cited by 2.4k
NY‐ESO‐1: Review of an Immunogenic Tumor AntigenSacha Gnjatic, Lloyd J. Old, Hiroyoshi Nishikawa et al.|Advances in cancer research|2006Cited by 455
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humansIan D. Davis, Jonathan Cebon, Weisan Chen et al.|Proceedings of the National Academy of Sciences|2004Cited by 440
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancersElke Jäger, Alexander Knuth, Sacha Gnjatic et al.|Proceedings of the National Academy of Sciences|2000Cited by 426
Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responsesElke Jäger, Alexander Knuth, Yasuhiro Nagata et al.|Proceedings of the National Academy of Sciences|2000Cited by 398